title: Shortening the infusion time of anticancer drugs: who will benefit?
authors.forename: Kim
authors.initials: K
authors.lastname: Margolin
authors.forename: Michael
authors.initials: M
authors.lastname: Gordon
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000191:economics; D000068258:Bevacizumab; D006801:Humans; D007262:Infusions, Intravenous; D008495:Medical Oncology / Q000191:economics / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy*; D011446:Prospective Studies; D011788:Quality of Life; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab